




MEDICINAL PRODUCTS 2023

Chemours Co
Rank 30 of 48





MEDICINAL PRODUCTS 2023

Chemours Co
Rank 30 of 48



The relative strengths and weaknesses of Chemours Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Chemours Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 54% points. The greatest weakness of Chemours Co is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 55% points.

The company's Economic Capital Ratio, given in the ranking table, is 22%, being 27% points above the market average of -5.0%.

Input Variable	Value in 1000 USD
Assets, Current	3,214,000
Assets, Non-Current	938,000
General and Administrative Expense	5,888,000
Goodwill	102,000
Liabilities, Current	1,952,000
Liabilities, Non-Current	4,581,000
Other Assets	215,000
Other Compr. Net Income	21,000
Other Expenses	342,000
Other Liabilities	0
Other Net Income	132,000
Other Revenues	6,794,000
Property, Plant and Equipment, Net	3,171,000
Research and Development	118,000

Output Variable	Value in 1000 USD
Liabilities	6,533,000
Assets	7,640,000
Expenses	6,348,000
Revenues	6,794,000
Stockholders Equity	1,107,000
Net Income	578,000
Comprehensive Net Income	588,500
Economic Capital Ratio	22%